|
(一) Agullo, G., Gamet-Payrastre, L., Manenti, S., Viala, C., Remesy, C., Chap, H., et al. (1997). Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol, 53(11), 1649-1657. Auer, K. L., Contessa, J., Brenz-Verca, S., Pirola, L., Rusconi, S., Cooper, G., et al. (1998). The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. Mol Biol Cell, 9(3), 561-573. Benvenuti, S., & Comoglio, P. M. (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol, 213(2), 316-325. Birchmeier, C., & Gherardi, E. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol, 8(10), 404-410. Birt, D. F., Hendrich, S., & Wang, W. (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther, 90(2-3), 157-177. Bishop, J. M. (1987). The molecular genetics of cancer. Science, 235(4786), 305-311. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., et al. (1991). Oncogenes and signal transduction. Cell, 64(2), 281-302. Cha, H. J., Bae, S. K., Lee, H. Y., Lee, O. H., Sato, H., Seiki, M., et al. (1996). Anti-invasive activity of ursolic acid correlates with the reduced expression of matrix metalloproteinase-9 (MMP-9) in HT1080 human fibrosarcoma cells. Cancer Res, 56(10), 2281-2284. Chauhan, S. S., Goldstein, L. J., & Gottesman, M. M. (1991). Expression of cathepsin L in human tumors. Cancer Res, 51(5), 1478-1481. Chowdhury, A. R., Sharma, S., Mandal, S., Goswami, A., Mukhopadhyay, S., & Majumder, H. K. (2002). Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem J, 366(Pt 2), 653-661. Christensen, J. G., Burrows, J., & Salgia, R. (2005). c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett, 225(1), 1-26. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., et al. (2003). A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res, 63(21), 7345-7355. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., et al. (1993). Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res, 53(22), 5365-5369. Delehedde, M., Sergeant, N., Lyon, M., Rudland, P. S., & Fernig, D. G. (2001). Hepatocyte growth factor/scatter factor stimulates migration of rat mammary fibroblasts through both mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt pathways. Eur J Biochem, 268(16), 4423-4429. Deryugina, E. I., & Quigley, J. P. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev, 25(1), 9-34. Dittmer, J. (2003). The biology of the Ets1 proto-oncogene. Mol Cancer, 2, 29. Evan, G. I., & Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature, 411(6835), 342-348. Furge, K. A., Zhang, Y. W., & Vande Woude, G. F. (2000). Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene, 19(49), 5582-5589. Giordano, S., Ponzetto, C., Di Renzo, M. F., Cooper, C. S., & Comoglio, P. M. (1989). Tyrosine kinase receptor indistinguishable from the c-met protein. Nature, 339(6220), 155-156. Gohda, E., Tsubouchi, H., Nakayama, H., Hirono, S., Sakiyama, O., Takahashi, K., et al. (1988). Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J Clin Invest, 81(2), 414-419. Hartmann, G., Weidner, K. M., Schwarz, H., & Birchmeier, W. (1994). The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem, 269(35), 21936-21939. Huang, C., Rajfur, Z., Borchers, C., Schaller, M. D., & Jacobson, K. (2003). JNK phosphorylates paxillin and regulates cell migration. Nature, 424(6945), 219-223. Huang, Y. T., Hwang, J. J., Lee, P. P., Ke, F. C., Huang, J. H., Huang, C. J., et al. (1999). Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br J Pharmacol, 128(5), 999-1010. Hunter, T., & Cooper, J. A. (1985). Protein-tyrosine kinases. Annu Rev Biochem, 54, 897-930. Ichihara, A. (1999). BCA, HGF, and proteasomes. Biochem Biophys Res Commun, 266(3), 647-651. Jiang, W. G., Martin, T. A., Parr, C., Davies, G., Matsumoto, K., & Nakamura, T. (2005). Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol, 53(1), 35-69. Jiang, Y., Xu, W., Lu, J., He, F., & Yang, X. (2001). Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1. Biochem Biophys Res Commun, 286(5), 1123-1130. Joseph, A., Weiss, G. H., Jin, L., Fuchs, A., Chowdhury, S., O''Shaugnessy, P., et al. (1995). Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst, 87(5), 372-377. Junbo, H., Li, Q., Zaide, W., & Yunde, H. (1999). Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis. In Vivo, 13(2), 177-180. Kim, M. H. (2003). Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. J Cell Biochem, 89(3), 529-538. Kimata, M., Inagaki, N., & Nagai, H. (2000). Effects of luteolin and other flavonoids on IgE-mediated allergic reactions. Planta Med, 66(1), 25-29. Ko, W. G., Kang, T. H., Lee, S. J., Kim, Y. C., & Lee, B. H. (2002). Effects of luteolin on the inhibition of proliferation and induction of apoptosis in human myeloid leukaemia cells. Phytother Res, 16(3), 295-298. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., & Pawson, T. (1991). SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science, 252(5006), 668-674. Kolibaba, K. S., & Druker, B. J. (1997). Protein tyrosine kinases and cancer. Biochim Biophys Acta, 1333(3), F217-248. Le Marchand, L. (2002). Cancer preventive effects of flavonoids--a review. Biomed Pharmacother, 56(6), 296-301. Lee, H. J., Wang, C. J., Kuo, H. C., Chou, F. P., Jean, L. F., & Tseng, T. H. (2005). Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol Appl Pharmacol, 203(2), 124-131. Lee, L. T., Huang, Y. T., Hwang, J. J., Lee, P. P., Ke, F. C., Nair, M. P., et al. (2002). Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells. Anticancer Res, 22(3), 1615-1627. Liotta, L. A. (1992). Cancer cell invasion and metastasis. Sci Am, 266(2), 54-59, 62-53. Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64(2), 327-336. Manthey, J. A., & Guthrie, N. (2002). Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J Agric Food Chem, 50(21), 5837-5843. Matrisian, L. M. (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet, 6(4), 121-125. Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., & Salgia, R. (2002). Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev, 13(1), 41-59. Menon, L. G., Kuttan, R., & Kuttan, G. (1995). Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett, 95(1-2), 221-225. Michalopoulos, G. K., & DeFrances, M. C. (1997). Liver regeneration. Science, 276(5309), 60-66. Mittra, B., Saha, A., Chowdhury, A. R., Pal, C., Mandal, S., Mukhopadhyay, S., et al. (2000). Luteolin, an abundant dietary component is a potent anti-leishmanial agent that acts by inducing topoisomerase II-mediated kinetoplast DNA cleavage leading to apoptosis. Mol Med, 6(6), 527-541. Monvoisin, A., Neaud, V., De Ledinghen, V., Dubuisson, L., Balabaud, C., Bioulac-Sage, P., et al. (1999). Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J Hepatol, 30(3), 511-518. Nakamura, T., Teramoto, H., & Ichihara, A. (1986). Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci U S A, 83(17), 6489-6493. Naldini, L., Vigna, E., Narsimhan, R. P., Gaudino, G., Zarnegar, R., Michalopoulos, G. K., et al. (1991). Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene, 6(4), 501-504. Naldini, L., Weidner, K. M., Vigna, E., Gaudino, G., Bardelli, A., Ponzetto, C., et al. (1991). Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J, 10(10), 2867-2878. Noji, S., Tashiro, K., Koyama, E., Nohno, T., Ohyama, K., Taniguchi, S., et al. (1990). Expression of hepatocyte growth factor gene in endothelial and Kupffer cells of damaged rat livers, as revealed by in situ hybridization. Biochem Biophys Res Commun, 173(1), 42-47. Paumelle, R., Tulasne, D., Kherrouche, Z., Plaza, S., Leroy, C., Reveneau, S., et al. (2002). Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene, 21(15), 2309-2319. Perez-Garcia, F., Adzet, T., & Canigueral, S. (2000). Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radic Res, 33(5), 661-665. Pierce, J. H., Ruggiero, M., Fleming, T. P., Di Fiore, P. P., Greenberger, J. S., Varticovski, L., et al. (1988). Signal transduction through the EGF receptor transfected in IL-3-dependent hematopoietic cells. Science, 239(4840), 628-631. Price, J. T., Bonovich, M. T., & Kohn, E. C. (1997). The biochemistry of cancer dissemination. Crit Rev Biochem Mol Biol, 32(3), 175-253. Reddy, K. B., Nabha, S. M., & Atanaskova, N. (2003). Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev, 22(4), 395-403. Rodrigues, G. A., Park, M., & Schlessinger, J. (1997). Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J, 16(10), 2634-2645. Rong, S., Segal, S., Anver, M., Resau, J. H., & Vande Woude, G. F. (1994). Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A, 91(11), 4731-4735. Rosen, E. M., Knesel, J., & Goldberg, I. D. (1991). Scatter factor and its relationship to hepatocyte growth factor and met. Cell Growth Differ, 2(11), 603-607. Ross, J. A., & Kasum, C. M. (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr, 22, 19-34. Rozhin, J., Gomez, A. P., Ziegler, G. H., Nelson, K. K., Chang, Y. S., Fong, D., et al. (1990). Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res, 50(19), 6278-6284. Schirmacher, P., Geerts, A., Pietrangelo, A., Dienes, H. P., & Rogler, C. E. (1992). Hepatocyte growth factor/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology, 15(1), 5-11. Seftor, R. E., Seftor, E. A., Stetler-Stevenson, W. G., & Hendrix, M. J. (1993). The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion. Cancer Res, 53(14), 3411-3415. Sharma, G. D., He, J., & Bazan, H. E. (2003). p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing: evidence of cross-talk activation between MAP kinase cascades. J Biol Chem, 278(24), 21989-21997. Shiota, G., Okano, J., Kawasaki, H., Kawamoto, T., & Nakamura, T. (1995). Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology, 21(1), 106-112. Sipeki, S., Bander, E., Buday, L., Farkas, G., Bacsy, E., Ways, D. K., et al. (1999). Phosphatidylinositol 3-kinase contributes to Erk1/Erk2 MAP kinase activation associated with hepatocyte growth factor-induced cell scattering. Cell Signal, 11(12), 885-890. Stupack, D. G., Cho, S. Y., & Klemke, R. L. (2000). Molecular signaling mechanisms of cell migration and invasion. Immunol Res, 21(2-3), 83-88. Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., et al. (1997). Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A, 94(2), 701-706. Takebayashi, T., Iwamoto, M., Jikko, A., Matsumura, T., Enomoto-Iwamoto, M., Myoukai, F., et al. (1995). Hepatocyte growth factor/scatter factor modulates cell motility, proliferation, and proteoglycan synthesis of chondrocytes. J Cell Biol, 129(5), 1411-1419. Taniguchi, S., Fujiki, H., Kobayashi, H., Go, H., Miyado, K., Sadano, H., et al. (1992). Effect of (-)-epigallocatechin gallate, the main constituent of green tea, on lung metastasis with mouse B16 melanoma cell lines. Cancer Lett, 65(1), 51-54. Tanimura, S., Chatani, Y., Hoshino, R., Sato, M., Watanabe, S., Kataoka, T., et al. (1998). Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene, 17(1), 57-65. Trusolino, L., & Comoglio, P. M. (2002). Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer, 2(4), 289-300. Ueda, H., Yamazaki, C., & Yamazaki, M. (2003). Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion. Biol Pharm Bull, 26(4), 560-563. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E. (1997). Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology, 25(3), 619-623. Ullrich, A., & Schlessinger, J. (1990). Signal transduction by receptors with tyrosine kinase activity. Cell, 61(2), 203-212. Watson, S. A., Morris, T. M., Robinson, G., Crimmin, M. J., Brown, P. D., & Hardcastle, J. D. (1995). Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res, 55(16), 3629-3633. Weidner, K. M., Sachs, M., & Birchmeier, W. (1993). The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J Cell Biol, 121(1), 145-154. Wolf, H. K., Zarnegar, R., & Michalopoulos, G. K. (1991). Localization of hepatocyte growth factor in human and rat tissues: an immunohistochemical study. Hepatology, 14(3), 488-494. Xia, Y., Makris, C., Su, B., Li, E., Yang, J., Nemerow, G. R., et al. (2000). MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A, 97(10), 5243-5248. Yang, C. S., Landau, J. M., Huang, M. T., & Newmark, H. L. (2001). Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr, 21, 381-406. Yoneda, J., Kuniyasu, H., Crispens, M. A., Price, J. E., Bucana, C. D., & Fidler, I. J. (1998). Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst, 90(6), 447-454. (二) Abdel-Ghany, M., Cheng, H. C., Elble, R. C., & Pauli, B. U. (2001). The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem, 276(27), 25438-25446. Abounader, R., & Laterra, J. (2005). Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro Oncol, 7(4), 436-451. Agullo, G., Gamet-Payrastre, L., Manenti, S., Viala, C., Remesy, C., Chap, H., et al. (1997). Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol, 53(11), 1649-1657. Baylin, S. B., & Ohm, J. E. (2006). Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer, 6(2), 107-116. Beecher, G. R. (2003). Overview of dietary flavonoids: nomenclature, occurrence and intake. J Nutr, 133(10), 3248S-3254S. Bigelow, R. L., & Cardelli, J. A. (2006). The green tea catechins, (-)-Epigallocatechin-3-gallate (EGCG) and (-)-Epicatechin-3-gallate (ECG), inhibit HGF/Met signaling in immortalized and tumorigenic breast epithelial cells. Oncogene, 25(13), 1922-1930. Billon, N., Carlisi, D., Datto, M. B., van Grunsven, L. A., Watt, A., Wang, X. F., et al. (1999). Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation. Oncogene, 18(18), 2872-2882. Birnbaum, M. J., van Wijnen, A. J., Odgren, P. R., Last, T. J., Suske, G., Stein, G. S., et al. (1995). Sp1 trans-activation of cell cycle regulated promoters is selectively repressed by Sp3. Biochemistry, 34(50), 16503-16508. Birt, D. F., Hendrich, S., & Wang, W. (2001). Dietary agents in cancer prevention: flavonoids and isoflavonoids. Pharmacol Ther, 90(2-3), 157-177. Birt, D. F., Mitchell, D., Gold, B., Pour, P., & Pinch, H. C. (1997). Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res, 17(1A), 85-91. Birt, D. F., Pelling, J. C., Nair, S., & Lepley, D. (1996). Diet intervention for modifying cancer risk. Prog Clin Biol Res, 395, 223-234. Bond, M., Chase, A. J., Baker, A. H., & Newby, A. C. (2001). Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc Res, 50(3), 556-565. Brownson, D. M., Azios, N. G., Fuqua, B. K., Dharmawardhane, S. F., & Mabry, T. J. (2002). Flavonoid effects relevant to cancer. J Nutr, 132(11 Suppl), 3482S-3489S. Camp, R. L., Rimm, E. B., & Rimm, D. L. (1999). Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer, 86(11), 2259-2265. Casagrande, F., & Darbon, J. M. (2001). Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol, 61(10), 1205-1215. Choi, J. H., Kwon, H. J., Yoon, B. I., Kim, J. H., Han, S. U., Joo, H. J., et al. (2001). Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res, 92(12), 1300-1304. Cress, W. D., & Seto, E. (2000). Histone deacetylases, transcriptional control, and cancer. J Cell Physiol, 184(1), 1-16. Cummings, S. R., Duong, T., Kenyon, E., Cauley, J. A., Whitehead, M., & Krueger, K. A. (2002). Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA, 287(2), 216-220. Czyz, J., Madeja, Z., Irmer, U., Korohoda, W., & Hulser, D. F. (2005). Flavonoid apigenin inhibits motility and invasiveness of carcinoma cells in vitro. Int J Cancer, 114(1), 12-18. Darnay, B. G., & Aggarwal, B. B. (1999). Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis, 58 Suppl 1, I2-I13. Davies, G., Jiang, W. G., & Mason, M. D. (2001). Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell-cell dissociation and in vitro invasion. Clin Cancer Res, 7(10), 3289-3297. de Rojas, V. R., Somoza, B., Ortega, T., & Villar, A. M. (1996). Different Mechanisms involved in the Vasorelaxant Effect of Flavonoids Isolated from Satureja obovata. Planta Med, 62(6), 554-556. Denhardt, D. T., Giachelli, C. M., & Rittling, S. R. (2001). Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol, 41, 723-749. DiGiuseppe, J. A., Weng, L. J., Yu, K. H., Fu, S., Kastan, M. B., Samid, D., et al. (1999). Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia, 13(8), 1243-1253. Dunnick, J. K., & Hailey, J. R. (1992). Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundam Appl Toxicol, 19(3), 423-431. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., et al. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell, 75(4), 817-825. Facchinetti, M. M., De Siervi, A., Toskos, D., & Senderowicz, A. M. (2004). UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase pathway. Cancer Res, 64(10), 3629-3637. Falcioni, R., Antonini, A., Nistico, P., Di Stefano, S., Crescenzi, M., Natali, P. G., et al. (1997). Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res, 236(1), 76-85. Fan, S., Gao, M., Meng, Q., Laterra, J. J., Symons, M. H., Coniglio, S., et al. (2005). Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene, 24(10), 1749-1766. Fiebig, H. H., Maier, A., & Burger, A. M. (2004). Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer, 40(6), 802-820. Forsberg, E. C., & Bresnick, E. H. (2001). Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays, 23(9), 820-830. Fotsis, T., Pepper, M. S., Aktas, E., Breit, S., Rasku, S., Adlercreutz, H., et al. (1997). Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res, 57(14), 2916-2921. Gallego, M. I., Bierie, B., & Hennighausen, L. (2003). Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene, 22(52), 8498-8508. Gartel, A. L., Goufman, E., Najmabadi, F., & Tyner, A. L. (2000). Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line. Oncogene, 19(45), 5182-5188. Gartel, A. L., & Tyner, A. L. (1999). Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res, 246(2), 280-289. Geahlen, R. L., Koonchanok, N. M., McLaughlin, J. L., & Pratt, D. E. (1989). Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. J Nat Prod, 52(5), 982-986. Ghosh, S., May, M. J., & Kopp, E. B. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 16, 225-260. Giordano, S., Bardelli, A., Zhen, Z., Menard, S., Ponzetto, C., & Comoglio, P. M. (1997). A point mutation in the MET oncogene abrogates metastasis without affecting transformation. Proc Natl Acad Sci U S A, 94(25), 13868-13872. Glaser, K. B., Li, J., Staver, M. J., Wei, R. Q., Albert, D. H., & Davidsen, S. K. (2003). Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun, 310(2), 529-536. Gohring, U. J., Bersch, A., Becker, M., Neuhaus, W., & Schondorf, T. (2001). p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. J Clin Pathol, 54(11), 866-870. Gong, R., Rifai, A., Tolbert, E. M., Centracchio, J. N., & Dworkin, L. D. (2003). Hepatocyte growth factor modulates matrix metalloproteinases and plasminogen activator/plasmin proteolytic pathways in progressive renal interstitial fibrosis. J Am Soc Nephrol, 14(12), 3047-3060. Gray, S. G., & Ekstrom, T. J. (2001). The human histone deacetylase family. Exp Cell Res, 262(2), 75-83. Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. Nature, 389(6649), 349-352. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O''Keefe, C. L., et al. (1994). Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev, 8(24), 2939-2952. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70. Hartmann, G., Weidner, K. M., Schwarz, H., & Birchmeier, W. (1994). The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J Biol Chem, 269(35), 21936-21939. Havsteen, B. (1983). Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol, 32(7), 1141-1148. Hebbes, T. R., Thorne, A. W., & Crane-Robinson, C. (1988). A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J, 7(5), 1395-1402. Henderson, I. C. (1993). Risk factors for breast cancer development. Cancer, 71(6 Suppl), 2127-2140. Hessenauer, A., Montenarh, M., & Gotz, C. (2003). Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol, 22(6), 1263-1270. Hiscox, S., & Jiang, W. G. (1999). Association of the HGF/SF receptor, c-met, with the cell-surface adhesion molecule, E-cadherin, and catenins in human tumor cells. Biochem Biophys Res Commun, 261(2), 406-411. Hofmann, G. E., Glatstein, I., Schatz, F., Heller, D., & Deligdisch, L. (1994). Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol, 170(2), 671-676. Huang, B. H., Laban, M., Leung, C. H., Lee, L., Lee, C. K., Salto-Tellez, M., et al. (2005). Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ, 12(4), 395-404. Huang, W., Tan, D., Wang, X., Han, S., Tan, J., Zhao, Y., et al. (2006). Histone deacetylase 3 represses p15(INK4b) and p21(WAF1/cip1) transcription by interacting with Sp1. Biochem Biophys Res Commun, 339(1), 165-171. Jeffers, M., Rong, S., & Vande Woude, G. F. (1996). Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol, 16(3), 1115-1125. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., et al. (2005). Cancer statistics, 2005. CA Cancer J Clin, 55(1), 10-30. Jiang, W. G., Martin, T. A., Parr, C., Davies, G., Matsumoto, K., & Nakamura, T. (2005). Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol, 53(1), 35-69. Kagawa, S., Fujiwara, T., Hizuta, A., Yasuda, T., Zhang, W. W., Roth, J. A., et al. (1997). p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. Oncogene, 15(16), 1903-1909. Kardassis, D., Papakosta, P., Pardali, K., & Moustakas, A. (1999). c-Jun transactivates the promoter of the human p21(WAF1/Cip1) gene by acting as a superactivator of the ubiquitous transcription factor Sp1. J Biol Chem, 274(41), 29572-29581. Kim, D., Kim, S., Koh, H., Yoon, S. O., Chung, A. S., Cho, K. S., et al. (2001). Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J, 15(11), 1953-1962. Kinzler, K. W., & Vogelstein, B. (1997). Cancer-susceptibility genes. Gatekeepers and caretakers. Nature, 386(6627), 761, 763. Kornberg, R. D., & Lorch, Y. (1999). Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell, 98(3), 285-294. Lania, L., Majello, B., & De Luca, P. (1997). Transcriptional regulation by the Sp family proteins. Int J Biochem Cell Biol, 29(12), 1313-1323. Lee, H., Rezai-Zadeh, N., & Seto, E. (2004). Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol, 24(2), 765-773. Lee, W. J., Wu, L. F., Chen, W. K., Wang, C. J., & Tseng, T. H. (2006). Inhibitory effect of luteolin on hepatocyte growth factor/scatter factor-induced HepG2 cell invasion involving both MAPK/ERKs and PI3K-Akt pathways. Chem Biol Interact, 160(2), 123-133. Lepley, D. M., & Pelling, J. C. (1997). Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinog, 19(2), 74-82. Li, B., & Birt, D. F. (1996). In vivo and in vitro percutaneous absorption of cancer preventive flavonoid apigenin in different vehicles in mouse skin. Pharm Res, 13(11), 1710-1715. Li, G., Schaider, H., Satyamoorthy, K., Hanakawa, Y., Hashimoto, K., & Herlyn, M. (2001). Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene, 20(56), 8125-8135. Li, J. M., & Brooks, G. (1999). Cell cycle regulatory molecules (cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors) and the cardiovascular system; potential targets for therapy? Eur Heart J, 20(6), 406-420. Lin, J. K., Chen, Y. C., Huang, Y. T., & Lin-Shiau, S. Y. (1997). Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J Cell Biochem Suppl, 28-29, 39-48. Liotta, L. A., Steeg, P. S., & Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64(2), 327-336. Liu, T., Kuljaca, S., Tee, A., & Marshall, G. M. (2006). Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev, 32(3), 157-165. Liu, Y. Z., Chrivia, J. C., & Latchman, D. S. (1998). Nerve growth factor up-regulates the transcriptional activity of CBP through activation of the p42/p44(MAPK) cascade. J Biol Chem, 273(49), 32400-32407. Liu, Y. Z., Thomas, N. S., & Latchman, D. S. (1999). CBP associates with the p42/p44 MAPK enzymes and is phosphorylated following NGF treatment. Neuroreport, 10(6), 1239-1243. Llorens, F., Miro, F. A., Casanas, A., Roher, N., Garcia, L., Plana, M., et al. (2004). Unbalanced activation of ERK1/2 and MEK1/2 in apigenin-induced HeLa cell death. Exp Cell Res, 299(1), 15-26. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature, 389(6648), 251-260. Luger, K., & Richmond, T. J. (1998). The histone tails of the nucleosome. Curr Opin Genet Dev, 8(2), 140-146. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., et al. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature, 375(6531), 503-506. Lund, A. H., & van Lohuizen, M. (2004). Epigenetics and cancer. Genes Dev, 18(19), 2315-2335. MacGregor, J. I., & Jordan, V. C. (1998). Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev, 50(2), 151-196. Maemura, M., Iino, Y., Yokoe, T., Horiguchi, J., Takei, H., Koibuchi, Y., et al. (1998). Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett, 126(2), 215-220. Mariotti, A., Kedeshian, P. A., Dans, M., Curatola, A. M., Gagnoux-Palacios, L., & Giancotti, F. G. (2001). EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion. J Cell Biol, 155(3), 447-458. Marks, P. A., Richon, V. M., Breslow, R., & Rifkind, R. A. (2001). Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol, 13(6), 477-483. Marks, P. A., Richon, V. M., Kelly, W. K., Chiao, J. H., & Miller, T. (2004). Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp, 259, 269-281; discussion 281-268. Maroni, P., Bendinelli, P., Matteucci, E., & Desiderio, M. A. (2007). HGF induces CXCR4 and CXCL12-mediated tumor invasion through Ets1 and NF-kappaB. Carcinogenesis, 28(2), 267-279. Martin, T. A., Parr, C., Davies, G., Watkins, G., Lane, J., Matsumoto, K., et al. (2003). Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis, 24(8), 1317-1323. Matrisian, L. M. (1990). Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet, 6(4), 121-125. McCawley, L. J., O''Brien, P., & Hudson, L. G. (1998). Epidermal growth factor (EGF)- and scatter factor/hepatocyte growth factor (SF/HGF)- mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP)-9. J Cell Physiol, 176(2), 255-265. McGill, C. J., & Brooks, G. (1995). Cell cycle control mechanisms and their role in cardiac growth. Cardiovasc Res, 30(4), 557-569. Mi, Z., Guo, H., Wai, P. Y., Gao, C., & Kuo, P. C. (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis, 27(6), 1134-1145. Mignatti, P., & Rifkin, D. B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev, 73(1), 161-195. Miranti, C. K., & Brugge, J. S. (2002). Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol, 4(4), E83-90. Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. (2001). The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res, 61(19), 7184-7188. Nakano, K., Mizuno, T., Sowa, Y., Orita, T., Yoshino, T., Okuyama, Y., et al. (1997). Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem, 272(35), 22199-22206. Nightingale, K. P., O''Neill, L. P., & Turner, B. M. (2006). Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev, 16(2), 125-136. Ocker, M., & Schneider-Stock, R. (2007). Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol, 39(7-8), 1367-1374. Owen, G. I., Richer, J. K., Tung, L., Takimoto, G., & Horwitz, K. B. (1998). Progesterone regulates transcription of the p21(WAF1) cyclin- dependent kinase inhibitor gene through Sp1 and CBP/p300. J Biol Chem, 273(17), 10696-10701. Park, B. K., Zeng, X., & Glazer, R. I. (2001). Akt1 induces extracellular matrix invasion and matrix metalloproteinase-2 activity in mouse mammary epithelial cells. Cancer Res, 61(20), 7647-7653. Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55(2), 74-108. Patel, D., Shukla, S., & Gupta, S. (2007). Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol, 30(1), 233-245. Pelicci, G., Giordano, S., Zhen, Z., Salcini, A. E., Lanfrancone, L., Bardelli, A., et al. (1995). The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene, 10(8), 1631-1638. Pepper, M. S., Matsumoto, K., Nakamura, T., Orci, L., & Montesano, R. (1992). Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem, 267(28), 20493-20496. Plaumann, B., Fritsche, M., Rimpler, H., Brandner, G., & Hess, R. D. (1996). Flavonoids activate wild-type p53. Oncogene, 13(8), 1605-1614. Ponzetto, C., Zhen, Z., Audero, E., Maina, F., Bardelli, A., Basile, M. L., et al. (1996). Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J Biol Chem, 271(24), 14119-14123. Potempa, S., & Ridley, A. J. (1998). Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol Biol Cell, 9(8), 2185-2200. Rabinovitz, I., Toker, A., & Mercurio, A. M. (1999). Protein kinase C-dependent mobilization of the alpha6beta4 integrin from hemidesmosomes and its association with actin-rich cell protrusions drive the chemotactic migration of carcinoma cells. J Cell Biol, 146(5), 1147-1160. Radhakrishnan, S. K., Feliciano, C. S., Najmabadi, F., Haegebarth, A., Kandel, E. S., Tyner, A. L., et al. (2004). Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene, 23(23), 4173-4176. Ravindranath, M. H., Muthugounder, S., Presser, N., & Viswanathan, S. (2004). Anticancer therapeutic potential of soy isoflavone, genistein. Adv Exp Med Biol, 546, 121-165. Reed, S. I., Bailly, E., Dulic, V., Hengst, L., Resnitzky, D., & Slingerland, J. (1994). G1 control in mammalian cells. J Cell Sci Suppl, 18, 69-73. Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., et al. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A, 95(6), 3003-3007. Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000). Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A, 97(18), 10014-10019. Richon, V. M., Webb, Y., Merger, R., Sheppard, T., Jursic, B., Ngo, L., et al. (1996). Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A, 93(12), 5705-5708. Ridley, A. J., Comoglio, P. M., & Hall, A. (1995). Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol, 15(2), 1110-1122. Romer, J., Bugge, T. H., Pyke, C., Lund, L. R., Flick, M. J., Degen, J. L., et al. (1996). Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med, 2(3), 287-292. Rose, D. P., Boyar, A. P., & Wynder, E. L. (1986). International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 58(11), 2363-2371. Rosenthal, E. L., Johnson, T. M., Allen, E. D., Apel, I. J., Punturieri, A., & Weiss, S. J. (1998). Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells. Cancer Res, 58(22), 5221-5230. Ross, J. A., & Kasum, C. M. (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr, 22, 19-34. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women''s Health Initiative randomized controlled trial. JAMA, 288(3), 321-333. Roth, S. Y., Denu, J. M., & Allis, C. D. (2001). Histone acetyltransferases. Annu Rev Biochem, 70, 81-120. Ruas, M., & Peters, G. (1998). The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta, 1378(2), F115-177. Saha, R. N., & Pahan, K. (2006). HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ, 13(4), 539-550. Sander, E. E., van Delft, S., ten Klooster, J. P., Reid, T., van der Kammen, R. A., Michiels, F., et al. (1998). Matrix-dependent Tiam1/Rac signaling in epithelial cells promotes either cell-cell adhesion or cell migration and is regulated by phosphatidylinositol 3-kinase. J Cell Biol, 143(5), 1385-1398. Schaeper, U., Gehring, N. H., Fuchs, K. P., Sachs, M., Kempkes, B., & Birchmeier, W. (2000). Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol, 149(7), 1419-1432. Sealy, L., & Chalkley, R. (1978). DNA associated with hyperacetylated histone is preferentially digested by DNase I. Nucleic Acids Res, 5(6), 1863-1876. Senderowicz, A. M. (2002). Cyclin-dependent kinases as new targets for the prevention and treatment of cancer. Hematol Oncol Clin North Am, 16(5), 1229-1253. Service, R. F. (1998). New role for estrogen in cancer? Science, 279(5357), 1631-1633. Shaw, L. M., Rabinovitz, I., Wang, H. H., Toker, A., & Mercurio, A. M. (1997). Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell, 91(7), 949-960. Shukla, S., & Gupta, S. (2004). Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog, 39(2), 114-126. Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H., et al. (2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol, 2(5), 249-256. Sliva, D., Rizzo, M. T., & English, D. (2002). Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem, 277(5), 3150-3157. Sommer, S., & Fuqua, S. A. (2001). Estrogen receptor and breast cancer. Semin Cancer Biol, 11(5), 339-352. Song, J., Noh, J. H., Lee, J. H., Eun, J. W., Ahn, Y. M., Kim, S. Y., et al. (2005). Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS, 113(4), 264-268. Thiagalingam, S., Cheng, K. H., Lee, H. J., Mineva, N., Thiagalingam, A., & Ponte, J. F. (2003). Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci, 983, 84-100. Thomas, T. J., Faaland, C. A., Adhikarakunnathu, S., Watkins, L. F., & Thomas, T. (1998). Induction of p21 (CIP1/WAF1/SID1) by estradiol in a breast epithelial cell line transfected with the recombinant estrogen receptor gene: a possible mechanism for a negative regulatory role of estradiol. Breast Cancer Res Treat, 47(2), 181-193. Toi, M., Taniguchi, T., Ueno, T., Asano, M., Funata, N., Sekiguchi, K., et al. (1998). Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res, 4(3), 659-664. Trusolino, L., Bertotti, A., & Comoglio, P. M. (2001). A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell, 107(5), 643-654. Trusolino, L., Cavassa, S., Angelini, P., Ando, M., Bertotti, A., Comoglio, P. M., et al. (2000). HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J, 14(11), 1629-1640. Tyson, J. J., Novak, B., Odell, G. M., Chen, K., & Thron, C. D. (1996). Chemical kinetic theory: understanding cell-cycle regulation. Trends Biochem Sci, 21(3), 89-96. van der Voort, R., Taher, T. E., Derksen, P. W., Spaargaren, M., van der Neut, R., & Pals, S. T. (2000). The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res, 79, 39-90. Vidali, G., Boffa, L. C., Bradbury, E. M., & Allfrey, V. G. (1978). Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci U S A, 75(5), 2239-2243. Vogelstein, B., & Kinzler, K. W. (2001). Achilles'' heel of cancer? Nature, 412(6850), 865-866. Wang, I. K., Lin-Shiau, S. Y., & Lin, J. K. (1999). Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer, 35(10), 1517-1525. Wang, W., VanAlstyne, P. C., Irons, K. A., Chen, S., Stewart, J. W., & Birt, D. F. (2004). Individual and interactive effects of apigenin analogs on G2/M cell-cycle arrest in human colon carcinoma cell lines. Nutr Cancer, 48(1), 106-114. Warn, R., Brown, D., Dowrick, P., Prescott, A., & Warn, A. (1993). Cytoskeletal changes associated with cell motility. Symp Soc Exp Biol, 47, 325-338. Way, T. D., Kao, M. C., & Lin, J. K. (2004). Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem, 279(6), 4479-4489. Weber, G. F., Ashkar, S., & Cantor, H. (1997). Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians, 109(1), 1-9. Wilson, A. J., Byun, D. S., Popova, N., Murray, L. B., L''Italien, K., Sowa, Y., et al. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem, 281(19), 13548-13558. Xiao, H., Hasegawa, T., & Isobe, K. (1999). Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem, 73(3), 291-302. Xie, D., Jauch, A., Miller, C. W., Bartram, C. R., & Koeffler, H. P. (2002). Discovery of over-expressed genes and genetic alterations in breast cancer cells using a combination of suppression subtractive hybridization, multiplex FISH and comparative genomic hybridization. Int J Oncol, 21(3), 499-507. Yamashita, Y., Kawada, S., & Nakano, H. (1990). Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem Pharmacol, 39(4), 737-744. Yang, C. S., Landau, J. M., Huang, M. T., & Newmark, H. L. (2001). Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr, 21, 381-406. Yao, P., Zhan, Y., Xu, W., Li, C., Yue, P., Xu, C., et al. (2004). Hepatocyte growth factor-induced proliferation of hepatic stem-like cells depends on activation of NF-kappaB. J Hepatol, 40(3), 391-398. Yin, F., Giuliano, A. E., Law, R. E., & Van Herle, A. J. (2001). Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Anticancer Res, 21(1A), 413-420. Yin, F., Giuliano, A. E., & Van Herle, A. J. (1999). Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid, 9(4), 369-376. Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990). Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem, 265(28), 17174-17179. Zeng, Q., Chen, S., You, Z., Yang, F., Carey, T. E., Saims, D., et al. (2002). Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. J Biol Chem, 277(28), 25203-25208. Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., et al. (2005). Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*. Breast Cancer Res Treat, 94(1), 11-16. Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., et al. (2004). HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res, 10(20), 6962-6968. Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., et al. (2006). Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol, 26(7), 2782-2790. Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K. P., & Gottlicher, M. (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell, 5(5), 455-463.
|